Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial -

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Respiratory disorders
Summary
Interim analysis (n=228) found bevacizumab plus erlotinib combination therapy improves progression-free survival vs. erlotinib alone (16.9 vs.13.3 months; HR 0.605, 95% CI 0.417–0.877; p=0·016). Studies with longer follow-up, overall survival and quality-of-life data are required
UKMi comment

A related commentary notes that the number of possible combinations and treatment sequences of EGFR TKIs, chemotherapy, bevacizumab, or anti-PD-1 and PD-L1 inhibitors complicate recommendations for first-line and second-line treatment in patients with NSCLC and EGFR mutations. At present, no biomarkers exist to enable the selection of the optimum treatment order for patients. Future studies might provide more evidence about treatment strategies.
Related links: Comment